Brookstone Capital Management Sells 193,541 Shares of Kenvue Inc. $KVUE

Key Points

• Brookstone Capital Management cut its Kenvue stake by 70.3% in the second quarter, selling 193,541 shares and retaining 81,929 shares valued at approximately $1.57 million.
• Kenvue reported quarterly EPS of $0.31, slightly below the $0.32 consensus estimate, while revenue rose 3% year over year to $3.96 billion.
• The company declared a quarterly dividend of $0.21 per share, equivalent to a 4.4% annualized yield; analysts remain cautious, with Kenvue carrying an overall “Hold” rating and an average price target of $19.27.

Brookstone Capital Management lowered its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 70.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 81,929 shares of the company's stock after selling 193,541 shares during the period. Brookstone Capital Management's holdings in Kenvue were worth $1,566,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the business. CoreCap Advisors LLC grew its position in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock valued at $29,000 after acquiring an additional 591 shares during the last quarter. Montag A & Associates Inc. raised its stake in Kenvue by 6.3% during the first quarter. Montag A & Associates Inc. now owns 10,156 shares of the company's stock worth $175,000 after acquiring an additional 600 shares in the last quarter. Cornerstone Wealth Group LLC lifted its holdings in shares of Kenvue by 5.9% in the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company's stock worth $187,000 after acquiring an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. lifted its holdings in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after acquiring an additional 618 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC boosted its stake in shares of Kenvue by 0.6% in the 4th quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company's stock valued at $2,143,000 after purchasing an additional 701 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE stock opened at $18.97 on Thursday. The firm has a market capitalization of $36.44 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 1.36 and a beta of 0.47. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The business's 50-day moving average price is $18.88 and its 200-day moving average price is $18.12. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $21.95.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business's quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.29 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue's payout ratio is 95.40%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research reports. Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, June 15th. UBS Group dropped their price objective on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Tuesday. Citigroup cut their target price on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 15th. Wall Street Zen cut shares of Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Zacks Research downgraded shares of Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, Kenvue currently has an average rating of "Hold" and an average target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source